Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethaverine SCHEMBL29355739 | 1.00 | PDE3A (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL29500886 | 1.00 | PDE3A (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL29624566 | 0.99 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL9614397 | 0.99 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL16180359 | 0.99 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL317507 | 0.99 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL30417501 | 0.99 | SMN1; SMN2 (1.00) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| Ethaverine SCHEMBL17603566 | 0.99 | PDE3A (0.97) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| SCHEMBL2455134 | 0.93 | PDE3A (0.87) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA | |
| SCHEMBL2460329 | 0.91 | PDE3A (0.83) | PDE3ASMN1; SMN2CYP3A4MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1004 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233483-A1 | COMPOUND AND METHOD FOR THE TREATMENT OF CORONAVIRUSES | APTEEUS (FR) | 2023-07-27 | — | — | US | claimed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | claimed |
| EP-4126234-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-02-08 | — | — | EP | claimed |
| WO-2022164850-A1 | COMPOUNDS TO PREVENT OR TREAT SARS-CoV-2 VARIANT INFECTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-08-04 | — | — | WO | claimed |
| WO-2021198440-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2021-10-07 | — | — | WO | claimed |
| WO-2021054927-A2 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2021-03-25 | — | — | WO | claimed |
| EP-3635130-A1 | PRECISION MEDICINE FOR TREATING AND PREVENTING SUICIDALITY | Indiana University Research and Technology Corporation (US) | 2020-04-15 | — | — | EP | claimed |
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | SOUTH DAKOTA BOARD OF REGENTS (US) | 2020-02-13 | — | — | US | claimed |
| WO-2018209341-A1 | PRECISION MEDICINE FOR TREATING AND PREVENTING SUICIDALITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-11-15 | — | — | WO | claimed |
| US-20170269060-A1 | Assays and Compounds to Treat Kidney Diseases | RUSH UNIVERSITY MEDICAL CENTER (US) | 2017-09-21 | — | — | US | claimed |
| WO-2002039952-A2 | SYNERGISTIC ECTA COMPOSITIONS | NEWBIOTICS, INC. (US) | 2002-05-23 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5491051-A | HAVING LIGHT SENSITIVE LAYER, TRANSPARENT MAGNETIC RECORDING LAYER CONTAINING TRANSPARENT BINDER, FERROMAGNETIC PARTICLES, ABRASIVE PARTICLES WITH SPECIFIED PROPERTIES; DURABILITY | EASTMAN KODAK COMPANY (US) | 1996-02-13 | — | — | US | claimed |
| US-5256652-A | Administering peripheral vasodilator and hydroxy-B-cyclo-dextrin to enhance erection | PHARMEDIC CO. (US) | 1993-10-26 | — | — | US | claimed |
| WO-1992003141-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT OF MALE IMPOTENCE | PHARMEDIC CO. (US) | 1992-03-05 | — | — | WO | claimed |
| US-5026544-A | Administering papaverine compound with interferon | BOARD OF REAGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-06-25 | — | — | US | claimed |
| US-4849412-A | PAPAVERINE COMPOUND, NUCLEOSIDE ANALOG | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-07-18 | — | — | US | claimed |
| WO-1987007508-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1987-12-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048305-A1 | GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS | GSTK1, GSTO1, GSTM2 | PDE3A 1351/4885SMN1; SMN2 4125/4885CYP3A4 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.